Quantitative Myasthenia Gravis Score (QMG)

Barohn RJ; McIntire D; Herbelin L; Wolfe GI; Nations SP; Bryan WW

Distributed by Mapi Research Trust


Distributed by Mapi Research Trust

Basic description

Published in 1983

The first version developed by Besinger UA was then modified in 1987 by Tindall RSA and again by Barohn RJ in 1998.


Barohn RJ; McIntire D; Herbelin L; Wolfe GI; Nations SP; Bryan WW

© 1997 UT Southwestern Medical Center, Dallas
To assess the degree of disease severity in Myasthenia Gravis (MG) patients
Therapeutic area
  • Nervous System Diseases
  • Immune System Diseases
  • Rare disease (Orphanet definition)
Therapeutic indication

Myasthenia Gravis For more information on this rare disease, please consult the following link: Orphanet page

Type of Clinical Outcome Assessment (COA)
  • perfo PerfO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Besinger UA, Toyka KV, Hömberg M, Heininger K, Hohlfeld R, Fateh-Moghadam A. Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology. 1983 Oct;33(10):1316-21 (PubMed abstract)

Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N Engl J Med. 1987 Mar 19;316(12):719-24 (Pubmed abstract)

Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann N Y Acad Sci. 1993 Jun 21;681:539-51 (Pubmed abstract)

Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW. Reliability testing of the quantitative myasthenia gravis score. Ann N Y Acad Sci. 1998 May 13;841:769-72 (Pubmed)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use


Barohn RJ; McIntire D; Herbelin L; Wolfe GI; Nations SP; Bryan WW

Richard J.Barohn, M.D.,
Professor of Neurology
Department of Neurology,
University of Kansas Medical Center
3901 Rainbow Boulevard
Mail Stop 2012
Kansas City, KS 66160
E-mail: rbarohn@kumc.edu

Richard J. Barohn's publications (PubMed)

Gil I. Wolfe, MD, FAAN
E-mail: gilwolfe@buffalo.edu

Laura Herbelin
E-mail: LHERBELIN@kumc.edu

Contact information

Mapi Research Trust
27 rue de la Villette
69003 Lyon
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access the questionnaire and/or its available translations directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.


Original language(s)

  • English for the USA


The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.


Czech for Czech Republic*
Dutch for Belgium (Flemish)*
English for Canada* L
English for the UK*
French for Belgium*
French for France*
German for Belgium*
German for Germany* L
Hungarian for Hungary*
Italian for Italy* L
Japanese for Japan* L
Korean for South Korea* L
Polish for Poland* L
Portuguese for Brazil
Portuguese for Portugal*
Russian for Russia*
Serbian for Serbia* L
Spanish for Spain* L
Spanish for the USA* L
Turkish for Turkey*
* Performed by Mapi/ICON
L Has undergone a Linguistic Validation methodology

Conditions to translate

Recommended vendor for translation work: Mapi/ICON Language Services

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

More information on translations

For information on, or permission to use the translations, please contact Mapi Research Trust.

Bibliographic reference of the Brazilian translation:

Oliveira EF, Valério BCO, Cavalcante V, Urbano JJ, Silva AS, Polaro MN, Nacif SR, Oliveira CS, Resende MBD, Oliveira ASB, Oliveira LVF. Quantitative Myasthenia Gravis Score: a Brazilian multicenter study for translation, cultural adaptation and validation. Arq Neuropsiquiatr. 2017 Jul;75(7):457-463 (Full text article)


Conditions to implement in electronic applications

Please refer to the "Contact and conditions of use" tab

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us